Evidence map›Paper›PMID 40381081›Full record

ReviewInternational ophthalmology2025

Ocular manifestations and treatment progress of Parry-Romberg syndrome.

Dengfeng Zhang, Shuting Huang, Xin Zhang, Le Ling, Bei Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Dengfeng ZhangDepartment of Ophthalmology, Chengdu Integrated TCM & Western Medicine Hospital /Chengdu First People's Hospital/Chengdu University of Traditional Chinese Medicine Affiliated Integrated TCM & Western Medicine Hospital, No.18 Wanxiang North Road, Chengdu, Sichuan Province, China.
Shuting HuangDepartment of Ophthalmology, Chengdu Integrated TCM & Western Medicine Hospital /Chengdu First People's Hospital/Chengdu University of Traditional Chinese Medicine Affiliated Integrated TCM & Western Medicine Hospital, No.18 Wanxiang North Road, Chengdu, Sichuan Province, China.
Xin ZhangDepartment of Ophthalmology, Chengdu Integrated TCM & Western Medicine Hospital /Chengdu First People's Hospital/Chengdu University of Traditional Chinese Medicine Affiliated Integrated TCM & Western Medicine Hospital, No.18 Wanxiang North Road, Chengdu, Sichuan Province, China.
Le LingDepartment of Ophthalmology, Chengdu Integrated TCM & Western Medicine Hospital /Chengdu First People's Hospital/Chengdu University of Traditional Chinese Medicine Affiliated Integrated TCM & Western Medicine Hospital, No.18 Wanxiang North Road, Chengdu, Sichuan Province, China.
Bei LiDepartment of Ophthalmology, Chengdu Integrated TCM & Western Medicine Hospital /Chengdu First People's Hospital/Chengdu University of Traditional Chinese Medicine Affiliated Integrated TCM & Western Medicine Hospital, No.18 Wanxiang North Road, Chengdu, Sichuan Province, China. apeidou@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposesParry-Romberg syndrome is a rare degenerative disease. This article focuses on the ocular aspects of Parry-Romberg syndrome to help diagnose and further explore more effective treatments.

methodsA combined systematic search of PubMed electronic database by using Boolean operators AND and OR was conducted, choosing the following keywords: "Parry-Romberg syndrome", "Progressive hemifacial atrophy", "eye", "oculus", "ophthalmic", "ophthalmologic", "ophthalmology" and "global", etc. After the initial screening of these articles, repetitive literatures were excluded.

results69 articles were selected. This study introduces the ocular manifestations, possible pathogenesis, and treatment progress of Parry-Romberg syndrome.

conclusionThere is currently no clear pathogenesis and effective treatment for Parry-Romberg syndrome. Understanding its pathological mechanism in the context of autoimmune etiology and exploring its phenotype-genotype correlation may help find more valuable treatments.

Indexed as

Eye DiseasesFacial HemiatrophyHumansManifestationsOcularParry-Romberg SyndromePathogenesisTreatment

Identifiers

PMID40381081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.